Randomised, Double-Blind, Placebo-Controlled, Multinational, Multi-Centre, Phase IIb/III Study of the Efficacy and Safety of Three Doses of Sublingual Immunotherapy (SLIT) Administered as Tablets Once Daily to Patients Suffering From Grass Pollen Rhinoconjunctivitis.

Trial Profile

Randomised, Double-Blind, Placebo-Controlled, Multinational, Multi-Centre, Phase IIb/III Study of the Efficacy and Safety of Three Doses of Sublingual Immunotherapy (SLIT) Administered as Tablets Once Daily to Patients Suffering From Grass Pollen Rhinoconjunctivitis.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs Grass pollen allergy immunotherapy (Primary)
  • Indications Grass pollen hypersensitivity; Rhinoconjunctivitis; Seasonal allergic rhinitis
  • Focus Therapeutic Use
  • Sponsors Stallergenes Greer plc; Stallergenes SA
  • Most Recent Events

    • 07 Nov 2012 Planned number of patients changed from 600 to 631 as reported by European Clinical Trials Database.
    • 13 Oct 2009 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
    • 18 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top